Neuronetics Inc Dossier
Qualitative Analysis
Business overview
Neuronetics, Inc. (NASDAQ: STIM) is a commercial-stage medical technology company focused on designing, developing, and marketing non-invasive treatments for patients suffering from psychiatric and neurohealth disorders. The company's flagship product is the NeuroStar Advanced Therapy System, which utilizes transcranial magnetic stimulation (TMS) to deliver a pulsed, MRI-strength magnetic field that stimulates specific areas of the brain associated with mood. NeuroStar is FDA-cleared and represents the leading TMS treatment for major depressive disorder (MDD). Following its strategic acquisition of Greenbrook TMS in late 2025, Neuronetics expanded its operations into two primary reporting segments: medical devices (NeuroStar systems and treatment sessions) and clinic services (direct outpatient mental health clinics).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A preferred partnership to integrate ANT Neuro's FDA-cleared visor2 neuronavigation system with the NeuroStar TMS platform, adding real-time spatial tracking and 3D visualization to treatment workflows.
Expected impact: Aims to support more personalized navigation, improve treatment consistency, and address evolving provider needs.
Optimizing marketing resources, digital patient outreach tools, and practice development materials to help provider customers identify patients who can benefit from NeuroStar TMS.
Expected impact: Aims to drive patient awareness, increase system utilization, and expand the network of active clinics.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To create a vertically integrated organization combining Neuronetics' NeuroStar technology platform with Greenbrook's nationwide network of treatment clinics, driving brand awareness, consistent delivery of best practices, and improved regional/national reimbursement.
Financial impact: Effectively doubled the revenue scale of the business, though it shifted the overall business mix toward lower-margin clinic services, reducing consolidated gross margins.
Strategic Partnerships
High; integrates advanced brain mapping and neuronavigation technologies directly into the NeuroStar TMS workflow to enhance clinical precision.
Terms: Preferred partnership terms; specific financial details were not disclosed.